Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation

Ann Hematol. 1992 May;64(5):249-52. doi: 10.1007/BF01738305.

Abstract

In two patients receiving L-asparaginase therapy, severe acute pancreatitis complicated by disseminated intravascular coagulation (DIC) developed. In both cases it was successfully treated with continuous infusion of a synthetic protease inhibitor, nafamostat mesilate. In this report, we briefly discuss the clinical efficacy of the synthetic protease inhibitor in treating such cases.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Asparaginase / adverse effects*
  • Asparaginase / therapeutic use
  • Benzamidines
  • Cyclophosphamide / administration & dosage
  • Disseminated Intravascular Coagulation / chemically induced*
  • Disseminated Intravascular Coagulation / complications
  • Female
  • Gabexate / therapeutic use
  • Guanidines / therapeutic use*
  • Humans
  • Male
  • Methotrexate / administration & dosage
  • Pancreatitis / chemically induced*
  • Pancreatitis / drug therapy*
  • Pancreatitis / prevention & control
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Prednisone / administration & dosage
  • Protease Inhibitors / therapeutic use*
  • Vincristine / administration & dosage

Substances

  • Benzamidines
  • Guanidines
  • Protease Inhibitors
  • Gabexate
  • Vincristine
  • Cyclophosphamide
  • Asparaginase
  • Prednisone
  • nafamostat
  • Methotrexate